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Problem Many resource-poor countries have started scaling up antiretroviral therapy (ART). While reports from individual clinics 
point to successful implementation, there is limited information about progress in government institutions at a national level.
Approach Malawi started national ART scale-up in 2004 using a structured approach. There is a focus on one generic, fixed-dose 
combination treatment with stavudine, lamivudine and nevirapine. Treatment is delivered free of charge to eligible patients with HIV 
and there is a standardized system for recruiting patients, monthly follow-up, registration, monitoring and reporting of cases and 
outcomes. All treatment sites receive quarterly supervision and evaluation.
Local setting In January 2004, there were nine public sector facilities delivering ART to an estimated 4 000 patients. By December 
2005, there were 60 public sector facilities providing free ART to 37 840 patients using national standardized systems. Analysis of 
quarterly cohort treatment outcomes at 12 months showed 80% of patients were alive, 10% dead, 9% lost to follow-up and 1% 
had stopped treatment.
Lessons learned Achievements were the result of clear national ART guidelines, implementing partners working together, an 
intensive training schedule focused on clinical officers and nurses, a structured system of accrediting facilities for ART delivery, 
quarterly supervision and monitoring, and no stock-outs of antiretroviral drugs. The main challenges are to increase the numbers 
of children, pregnant women and patients with tuberculosis being started on ART, and to avert high early mortality and losses to 
follow-up. The capacity of the health sector to cope with escalating case loads and to scale up prevention alongside treatment will 
determine the future success of ART delivery in Malawi.
Bulletin of the World Health Organization 2007;85:156-160.
Une traduction en français de ce résumé figure à la fin de l’article.  Al final del artículo se facilita una traducción al español.
Background
In December 2003, the World Health 
Organization(WHO) and the joint 
United Nations Programme on HIV 
and AIDS (UNAIDS) launched the “3 
by 5” initiative, with the goal of hav-
ing 3 million people on antiretroviral 
therapy (ART) in developing countries 
by the end of 2005. By December 2005, 
an estimated 1.3 million people from 
low- and middle-income countries had 
started treatment, with 810 000 of these 
living in sub-Saharan Africa.1
Although the 3 by 5 target was not 
reached, it has been a remarkable effort, 
particularly in the challenging working 
arena of sub-Saharan Africa. Reports 
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from clinics in Botswana,2 Kenya,3 
Uganda 4 and other African countries 5 
have shown that ART can be delivered 
successfully to HIV-infected eligible 
patients with excellent clinical and im-
munological benefit. However, despite 
these encouraging successes, there is 
limited information about how ART 
delivery has fared in the routine govern-
ment health services of resource-poor 
African countries.
In Malawi, we embarked on na-
tional scale-up of ART through govern-
ment and mission health facilities in 
early 2004. With 170 000 HIV-infected 
patients thought to be in need of ART,6 
the country set a target to have 80 000 
patients on treatment by the end of 
2005. This goal was in line with the 
WHO initiative to place half the patients 
in need of ART in developing coun-
tries on treatment by 2005. We have 
previously reported on progress made 
during 2004,7 and here we report on 
Malawi’s achievements and the techni-
cal challenges faced during the “3 by 5” 
campaign up to December 2005.
Scale-up methods
Details of ART delivery in Malawi 
between 2004 and 2005 have been de-
scribed elsewhere.8 A standardized struc-
tured approach was used for treatment, 
details of which are shown in Box 1.
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Table 1. Characteristics and outcomes of 37 840 patients starting antiretroviral 
treatment in Malawi, 2004 – 2005
Characteristic Number (%)a
Male  1 4819  (39%)
Female  2 3021  (61%)
Adults (age >13 years)  3 5841  (95%)
Children (age <12 years)  1999  (5%)
Occupation recorded 26 172 (69%)
Housewife  5 895  (23%)
Farmer  6 035  (23%)
Small-scale business employee  3 669  (14%)
Army or police force employee  559  (2%)
Teacher  1 127  (4%)
Health care worker  616  (2%)
Other  8 271  (31%)
Occupation not recorded  11 668  (31%)
Reason for starting ARTb
Stage IIIc  24 712  (65%)
Stage IVc  9 232  (24%)
Stage I or IIc with CD4 count < 200/mm³  3 896  (10%) 
Outcome 
Alive and on ART at the initial ART registration siteb  28 110  (74%)
On first line regimen  27 066  (96%)
On alternative first line regimen due to side-effects  983  (3%)
On second line regimen due to treatment failure  61  (<1%)
Able to walk at home unaided d  26 846  (96%)
Able to do productive workd  25 964  (93%)
Significant side-effects present in December 2005e  1 159  (5%)
Drug adherence >95% measured by pill counts f  19 254  (91%)
Transferred out to another ART registration site  2 466  (7%)
Dead  3 923  (10%)
Died in month 1  1 439  (37%)
Died in month 2  897  (23%)
Died in month 3  438  (11%)
Died in month 4 or later  1 149  (29%)
Lost to follow-up (not seen at the clinic for > 3 months)  3 047  (8%)
Permanently stopped ARTb  294  (1%)
a  Percentages may not add to 100 because of rounding.
b  ART, antiretroviral therapy.
c  WHO clinical staging system for HIV.
d  Data known for 27894 patients
e  Data known for 25151 patients.
f Data Known for 21101 patients.
With the shortage of doctors in 
Malawi, paramedical clinical officers 
and medical assistants and nurses were 
trained to manage and deliver ART. 
The HIV Unit of the Ministry of Health 
and selected partners developed a 5-day 
training module and a certification of 
competence linked to a formal exami-
nation, and successful participants then 
undertook a 2-week practical clinical 
attachment at one of the experienced 
ART sites. The HIV Unit and the same 
selected partners implemented the train-
ing by mid-2004. By the end of 2005, 
1138 health care workers in the public 
sector including 118 doctors, 384 clini-
cal officers, 23 medical assistants and 
613 nurses had been trained and certified 
in ART management.
Sixty facilities in the public health 
sector were selected for ART scale-up 
between 2004 and 2005, with each site 
being accredited by the HIV Unit of 
the Ministry of Health before being al-
lowed to deliver ART. At the beginning 
of 2004, nine public health facilities 
were delivering ART using their own 
systems and treatments. By July 2005 
there were 60 facilities, all of which were 
delivering ART using national standard-
ized systems.
Results
In early 2004, an estimated 4000 pa-
tients had started on ART in the public 
health sector. By the end of 2005, the 
number of patients cumulatively started 
on ART was 37 840, which was 47% of 
the national target. Characteristics and 
outcomes of patients started on ART 
are shown in Table 1. ART was given 
to 6680 patients with active or previous 
tuberculosis, who as a result were staged 
in WHO clinical stage III or stage IV 
(18% of those placed on ART), and 
336 HIV-positive pregnant women 
through Prevention of Mother to Child 
Transmission programmes (1% of those 
placed on ART).
For reporting purposes, cohorts of 
patients are grouped by quarters of the 
calendar year, allowing 6-month and 
12-month cohort outcome analyses to 
be performed. For example, all patients 
registered in a cohort from January to 
March 2005 could have their outcomes 
assessed on 30 September 2005, and 
these data were included in the 6-month 
outcome analysis (although we do rec-
ognize that this method includes patient 
outcomes 6–9 months after starting 
ART). This same cohort at a later time 
could also have their outcomes assessed 
on 31 March 2006, with these data be-
ing included in the 12-month outcome 
analysis.
During each of the supervisory and 
monitoring visits in 2005 and 2006, 
data from all cohorts of patients at the 
ART facilities were included in 6-month 
and 12-month outcome analyses: these 
were combined to give results which are 
shown in Fig.1. Outcomes at 6 months 
and 12 months were similar, indicating 
that most deaths in a young programme 




The Malawian example that we describe 
shows that using a simple, structured 
approach to ART delivery, government 
health sectors can deliver treatment to 
large numbers of patients fairly quickly 
with good outcomes. A few facilities in 
Malawi are supported by international 
organizations, such as Médecins sans 
Frontières, but in most facilities local 
health care workers are the sole pro-
viders of ART. Although the national 
target for numbers of people on ART 
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Fig. 1. Six-month and 12-month outcomes for patients started on antiretroviral 


































Box 1. Standardized approach for delivery of antiretroviral treatment in Malawi
• A focus on one generic, fixed-dose combination treatment with stavudine, lamivudine and 
nevirapine. Treatment is delivered free of charge to eligible HIV-positive patients.
• The initiation of treatment at antiretroviral treatment clinics that included: patient referral 
from HIV testing sites for clinical staging; attendance of the patient and a guardian at a group 
counselling session where the principles of ART are described; re-attendance about 1 week 
later for individual counselling with the clinician and the start of treatment. The process from 
clinical staging to the start of ART takes on average about 2 weeks. 
• Monthly follow-up of patients, with usually only clinical criteria (for example, weight gain) 
and the presence or absence of side effects being used to judge treatment progress. 
• Use of a standardized system for registration, monitoring and reporting of cases and 
outcomes. 
• Quarterly supervision and evaluation of all antiretroviral treatment sites.
was not reached, there has been general 
satisfaction to date with the achievement 
in ART scale-up, especially given that 
trained health care personnel, monitor-
ing tools and systems of drug procure-
ment and distribution were not in place 
at the beginning of 2004.
There have been several factors re-
sponsible for the successes in ART deliv-
ery in Malawi. The most important are: 
clear national ART guidelines, with an 
emphasis on the system of registration, 
monitoring and recording of results; 
agreement by all implementing partners 
to work with the Ministry of Health and 
use national standardized systems; an 
intensive training schedule focused on 
clinical officers and nurses learning the 
ART guidelines; a structured system of 
accrediting ART sites before they are per-
mitted to deliver treatment to patients; 
quarterly supervision and monitoring of 
all ART delivery sites by the HIV Unit of 
the Ministry of Health and its partners; 
and an ART procurement and distribu-
tion system that was associated with no 
stock-outs of antiretroviral drugs. ART 
facilities vary in their quality and some 
do not perform as well as they should. 
However, regular and structured su-
pervision ensures that a basic standard 
is always maintained and that data are 
always collected.
Challenges
There have been several challenges in 
the scaling-up of ART delivery. Chil-
dren, HIV-positive pregnant women 
and patients with tuberculosis were, 
and still are, under-represented in treat-
ment populations. The new revised 
2006 WHO Paediatric Guidelines,9 
and Malawi’s revised ART Guidelines,10 
which emphasize the importance of 
ART for children and recommend pri-
oritizing CD4-lymphocyte counts in 
HIV-infected pregnant women, should 
increase the number of children and 
pregnant women accessing ART. Tuber-
culosis remains a difficult problem as a 
result of drug-drug interactions be-
tween rifampicin and non-nucleoside 
reverse transcriptase inhibitors 11 and 
the fact that in Malawi ART is usually 
distributed from hospital clinics, whereas 
delivery of anti-tuberculosis treatment 
is decentralized and is done from health 
centres.12
There is a high early death rate 
in patients starting ART, similar to 
that reported from other low-income 
countries.13 This finding is related to 
patients presenting with advanced HIV 
disease, tuberculosis, bacterial infections, 
malignancy and immune reconstitution 
syndrome.14 An aggressive approach 
to the diagnosis of tuberculosis before 
initiating ART and concomitant broad-
spectrum antibiotic prophylaxis targeted 
at common serious bacterial infections 
may be two ways to reduce this problem 
of early deaths. The number of cases 
lost to follow-up is also of concern, and 
operational research is needed to identify 
the true outcomes of these patients to 
establish a more complete data set for 
analysis.
Other challenges to ART scale-up 
include equitable access to ART sites 
especially for patients in rural areas, the 
capacity of the health sector to absorb the 
extra demands of ART delivery without 
compromising other aspects of general 
health care, and the scaling-up of preven-
tion efforts alongside treatment.15  O
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Résumé
La contribution du Malawi à l’initiative « trois millions d’ici 2005 » : résultats obtenus et défis à relever
Problématique De nombreux pays pauvres en ressources 
ont entamé l’extension du traitement antirétroviral (ART). Si les 
informations provenant des différents établissements font état d’une 
mise en œuvre satisfaisante, les données restent limitées quant aux 
progrès accomplis par les services publics au niveau national.
Démarche Le Malawi a commencé l’extension du traitement 
antirétroviral au niveau national en 2004 au moyen d’une 
approche structurée utilisant principalement une association fixe 
de type générique, associant stavudine, lamivudine et néviparine. 
Le traitement est fourni gratuitement aux sujets porteurs du VIH 
et remplissant les critères d’inclusion et un système normalisé 
est appliqué pour le recrutement des malades, le suivi mensuel, 
l’enregistrement et la surveillance, ainsi que pour la notification des 
cas et des issues du traitement. Une supervision et une évaluation 
trimestrielles sont assurées dans tous les centres de traitement.
Situation locale En janvier 2004, un traitement antirétroviral était 
fourni à quelque 4000 malades dans neuf centres relevant du secteur 
public. En décembre 2005, 60 de ces centres délivraient gratuitement 
des antirétroviraux à 37 840 malades par l’intermédiaire de 
systèmes nationaux normalisés. L’analyse des résultats trimestriels 
du traitement pour les cohortes a montré qu’au bout de 12 mois 
80 % des sujets étaient en vie, 10 % étaient décédés, alors qu’on 
avait perdu la trace de 9 % d’entre eux et qu’on enregistrait 1 % 
d’abandons du traitement.
Enseignements tirés Les résultats ont pu être obtenus grâce à 
des directives nationales claires sur le traitement antirétroviral, à 
la collaboration entre les partenaires chargés de la mise en œuvre, 
à une formation intensive des cliniciens et des infirmières, à un 
système structuré d’accréditation des centres appelés à délivrer 
le traitement, à une supervision et une surveillance trimestrielles, 
ainsi qu’à un approvisionnement continu en antirétroviraux. 
Les principaux défis consistent à améliorer le nombre - limité 
au demeurant - d’enfants, de femmes enceintes et de malades 
souffrant de la tuberculose et entamant un traitement ARV et à 
réduire la forte mortalité précoce et le nombre de sujets perdus 
de vue.  L’aptitude du secteur de la santé à faire face au nombre 
sans cesse plus élevé de cas et à étendre les activités de prévention 
en plus du traitement est aussi une source de préoccupations. 
C’est la capacité à relever ces défis qui conditionnera le succès 
du traitement antirétroviral au Malawi.
Resumen
La contribución de Malawi a la iniciativa «tres millones para 2005»: logros y retos
Problema Muchos países con escasos recursos han iniciado 
una expansión del tratamiento antirretrovírico (TAR). Aunque 
los informes de algunas clínicas señalan el éxito de la iniciativa, 
hay escasa información sobre los progresos realizados en las 
instituciones gubernamentales a nivel nacional.
Estrategia Malawi comenzó en 2004 la expansión nacional del 
TAR con una estrategia estructurada, centrada en el tratamiento 
con un genérico consistente en la combinación de estavudina, 
lamivudina y nevirapina a dosis fijas. El tratamiento es ofrecido 
gratuitamente a los pacientes infectados por VIH que cumplen 
los criterios, y hay un sistema normalizado de reclutamiento de 
los pacientes, seguimiento mensual, registro, y monitorización 
y notificación de los casos y los resultados. Todos los lugares 
donde se dispensa el tratamiento son supervisados y evaluados 
trimestralmente.
Entorno local En enero de 2004 había nueve centros del 
sector público que proporcionaban TAR a unos 4 000 pacientes. 
En diciembre de 2005 había 60 centros del sector público que 
proporcionaban TAR gratuito a 37 840 pacientes en el marco de 
los sistemas nacionales normalizados. El análisis de los resultados 
trimestrales del tratamiento de las cohortes a los 12 meses reveló 
que el 80% de los pacientes estaban vivos y el 10% muertos, 
mientras que en el 9% se había interrumpido el seguimiento y en 
el 1% se había detenido el tratamiento.
Enseñanzas Los logros se debieron a la existencia de directrices 
nacionales claras sobre el TAR, al trabajo en colaboración con 
los asociados, a un plan intensivo de formación centrado en los 
ayudantes clínicos y las enfermeras, a un sistema estructurado de 
acreditación de los centros dispensadores de TAR, a la supervisión 
y monitorización trimestrales, y al hecho de que nunca se agotaran 
las existencias de antirretrovíricos. Los principales retos consisten 
en aumentar el número de niños, embarazadas y pacientes 
tuberculosos que reciben TAR, y evitar la elevada mortalidad inicial 
y las interrupciones del seguimiento. La capacidad del sector 
de la salud para hacer frente al aumento del número de casos 
y la ampliación de la prevención a la par del tratamiento serán 
determinantes del éxito futuro del TAR en Malawi.
صخلم
تايدحتلاو تازاجنلإا :5 في 3 ةردابم في يولام ةمهاسم
 ةجلاعلما  قاطن  عيسوت  في  دراولما  ةيرقفلا  نادلبلا  نم  ديدعلا  أدب  :ةلكشلما
 نم  ةدراولا  ريراقتلا  يرشت  ينح فيو .ةيرقهقلا  تاسويرفلل  ةداضلما  ةيودلأاب
 تامولعلما  في  ًاصقن  كلانه  نأ  لاإ  ،يعاسلما  هذه حاجن  لىإ  ةصاخ  تادايع
.ينطولا ىوتسلما لىع ةيموكحلا تاسسؤلما في زرحلما م ُّدقتلاب ةقلعتلما
 ماع في ينطولا ىوتسلما لىع ةجلاعلما قاطن عيسوت في يولام تأدب :بولسلأا
 سينج ءاود مادختسا لىع ةجلاعلما تز َّكرـتو .يجهنم بولسأ عابتاب 2004
 ،نيدوفاتسلا نم ن َّوكتـت ةعرجلا ةتباث ةفيلوت وهو ،دحاو )ةيكللما ددحم يرغ(
 زديلإا  سويرفب  ينباصملل  ًاناجم  ةجلاعلما  م ُّدقتو  .ينبايرفنلاو  ،نيدوفيملالاو
 ةعباتمللو ،ضىرلما ينـيعتل ًادحوم ًاماظن كلانه نأ ماك ،ةجلاعملل ينقحتسلما
 فاشرلإا متيو .جئاتنلا نعو اهنع غيلبتلاو تلااحلا دصرلو ليجستللو ،ةيرهشلا
.رهشأ ةثلاث لك ًايرود عقاولما عيمج لىع ميـيقتلاو
 ةعبات  قفارم ةعست كلانه ناك 2004  رياني/نياثلا  نوناك في :ليحلما عقولما
 فلاآ  4  وحنل  ةيرقهقلا  تاسويرفلا  تاداضبم  ةجلاعلما  مدقت  ماعلا  عاطقلل
 في  قفارلما  كلت  ددع  دادزا  .2005  برمسيد/لولأا  نوناك  لولحبو  .ضيرم
 ًاضيرم  37840  وحنل  ةيناجلما  ةجلاعلما  مدقت  ًاقفرم  60  لىإ  ماعلا  عاطقلا
 ةجلاعم  جئاتن  ليلحت  ينبيو  .ةجلاعملل  ةيسايقلا  ةينطولا  مظنلا  مادختساب
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 ضىرلما نم %80 ناك ًارهش 12 دعب هنأ ،رهشأ ةثلاث لك يرجأ يذلا ،ضىرلما
 ،ةعباتلما نم اودقُف %9و ،مهنم %10 تام مايف ،ةايحلا ديق لىع نولازيلا
.ةجلاعلما اوفقوأ %1و
 ةيداشرإ لئلاد دوجو لىإ تق َّقحت يتلا تازاجنلإا ىزعُت :ةدافتسلما سوردلا
 ،ءاكشرلا نواعت لىإو ،ةيرقهقلا تاسويرفلا تاداضبم ةجلاعملل ةحضاو ةينطو
 دوجو لىإو ،تاضرملماو ءابطلأا لىع زّكري بيردتلل فثكم جمانرب دوجو لىإو
 ،ةيرقهقلا  تاسويرفلل  ةداضلما  ةجلاعلما  ءاتيإ  قفارم  دماتعلا  يجهنم  ماظن
 ةيودأ  نوزخم  دافن  مدع  لىإو  ،رهشأ  ةثلاث  لك  قفارلما  كلت  لىع  فاشرلإلو
 لماوحلاو  لافطلأا  ددع  ةدايز  في  ةيسيئرلا  تايدحتلا  لّـَ ثمتـتو  .ةجلاعلما
 ،ةركبلما تايفولا لدعم عافتراو ،ةجلاعلما لىع نولصحي نيذلا لسلا ضىرمو
 ءابعلأا  لىع  بُّلغتلا  لىع  يحصلا  عاطقلا  ةردق  ينسحت  فيو  ،ةعباتلما  مدعو
 .ةجلاعلما  بناج  لىإ  ةياقولا  ةطشنأب  ضوهنلا  ةيفيكو  ،ةدعاصتلما  ةيضرلما
 ليبقتسلما حاجنلا ىدم ررقت فوس تايدحتلا هذه ةهجاوم لىع انتردق نإ
.يولام في ةيرقهقلا تاسويرفلا تاداضبم ةجلاعلما ميدقتل
Corrigenda
In Vol. 84, issue number 12, 2006, page 980, the first sentence 
in the second paragraph under “Overweight and obesity” should 
read as follows:
“We calculated the percentage of males and females who 
were overweight and obese in each quintile over time [data not 
shown].” 
In Vol. 84, issue number 8, 2006, page 615, Figure 3 should be:
